Memo Therapeutics
Biotechnology company discovering and developing fully human antibodies from immune memory B cells for the treatment of infectious diseases and other therapeutic areas.
Location
Basel, Switzerland
Founded
2018
Investors
1
Categories
biotech, antibody-therapeutics, infectious-disease, immunology, vaccines
Notes
Memo Therapeutics is a biotechnology company pioneering the discovery of therapeutic antibodies directly from human immune memory. The company's proprietary platform identifies and develops fully human antibodies by accessing the immune memory encoded in B cells from individuals who have successfully fought off infections.
Based in Basel, Switzerland, Memo Therapeutics is part of the Adjuvant Capital portfolio and focuses on developing antibody-based therapies for infectious diseases, including emerging viral threats and antimicrobial-resistant bacteria.
Team
- Information on leadership team pending further research
Additional Research Findings
- Founded in 2018
- Headquarters in Basel, Switzerland
- Portfolio company of Adjuvant Capital
- Proprietary immune memory B cell platform
- Fully human antibody discovery
- Focus on infectious diseases
- Potential applications in pandemic preparedness
- Swiss biotech ecosystem
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |